Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Income taxes - deferred | 2,154,000 | 137,000 | 1,019,000 | 1,948,000 | N/A |
| Accounts receivable | -495,000 | 442,000 | -202,000 | 156,000 | 123,000 |
| Other Working Capital | 1,488,000 | 757,000 | 267,000 | -2,420,000 | -1,771,000 |
| Other Operating Activity | -578,000 | 3,840,000 | 6,138,000 | 4,691,000 | 7,898,000 |
| Operating Cash Flow | $2,569,000 | $5,176,000 | $7,222,000 | $4,375,000 | $6,250,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,308,000 | -1,149,000 | -1,142,000 | -983,000 | -823,000 |
| Net Acquisitions | 7,528,000 | 235,000 | 1,951,000 | -2,535,000 | -264,000 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -111,000 |
| Sale Of Investment | N/A | N/A | 15,000 | 224,000 | 1,132,000 |
| Purchase Sale Intangibles | -285,000 | -233,000 | -377,000 | 587,000 | -168,000 |
| Other Investing Activity | 338,000 | 399,000 | 213,000 | 1,132,000 | 359,000 |
| Investing Cash Flow | $6,037,000 | $-1,078,000 | $524,000 | $-2,631,000 | $-112,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -2,412,000 | -1,709,000 | -1,872,000 | -816,000 | 37,000 |
| Debt Issued | N/A | 1,960,000 | 1,913,000 | 4,430,000 | N/A |
| Common Stock Issued | 73,000 | 167,000 | 585,000 | 414,000 | 295,000 |
| Common Stock Repurchased | -99,000 | -333,000 | -1,549,000 | -2,530,000 | -2,227,000 |
| Dividend Paid | -3,874,000 | -3,843,000 | -3,680,000 | -3,814,000 | -3,406,000 |
| Other Financing Activity | -791,000 | -1,627,000 | -1,670,000 | -1,035,000 | -931,000 |
| Financing Cash Flow | $-7,103,000 | $-5,385,000 | $-6,273,000 | $-3,351,000 | $-6,232,000 |
| Exchange Rate Effect | -45,000 | 84,000 | -148,000 | -92,000 | -108,000 |
| Beginning Cash Position | 4,028,000 | 5,231,000 | 3,906,000 | 5,605,000 | 5,807,000 |
| End Cash Position | 5,486,000 | 4,028,000 | 5,231,000 | 3,906,000 | 5,605,000 |
| Net Cash Flow | $1,503,000 | $-1,287,000 | $1,473,000 | $-1,607,000 | $-94,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,569,000 | 5,176,000 | 7,222,000 | 4,375,000 | 6,250,000 |
| Capital Expenditure | -1,901,000 | -1,751,000 | -1,701,000 | -1,520,000 | -1,328,000 |
| Free Cash Flow | 668,000 | 3,425,000 | 5,521,000 | 2,855,000 | 4,922,000 |